Vaccine-derived polioviruses

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S283-S293

  Burns, Cara C ^a   Diop, Ousmane M ^b   Sutter, Roland W ^b   Kew, Olen M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

OPV; oral poliovirus vaccine; poliomyelitis; poliovirus; vaccine derived poliovirus; VDPV

Indexed keywords

BIVALENT ORAL POLIOMYELITIS VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; PROTEIN VP1; TRIVALENT ORAL POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE;

ACUTE FLACCID PARALYSIS; AMBIGUOUS VACCINE DERIVED POLIOVIRUS; ARTICLE; CIRCULATING VACCINE DERIVED POLIOVIRUS; DISEASE ERADICATION; DISEASE SURVEILLANCE; EPIDEMIC; FLACCID PARALYSIS; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNODEFICIENCY ASSOCIATED VACCINE DERIVED POLIOVIRUS; INCIDENCE; INFECTION RISK; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PUBLIC HEALTH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SEROTYPE; STRAIN DIFFERENCE; STRAIN IDENTIFICATION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; VACCINE DERIVED POLIOVIRUS; VIRUS EXCRETION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; CLASSIFICATION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; PATHOGENICITY; VIRULENCE; VIRUS SHEDDING;

GENOTYPE; HUMANS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINES, ATTENUATED; VIRULENCE; VIRUS SHEDDING;

EID: 84910599769     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu295     Document Type: Article

References (86)

1. Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. London: W. B. Saunders, 2013:598-645.
2. Centers for Disease Control and Prevention. Progress toward eradication of polio-worldwide, January 2011-March 2013. Morbid Mortal Wkly Rep 2013; 62:335-8.
3. Cochi SL, Jafari HS, Armstrong GL, et al. Aworld without polio. J Infect Dis 2014; 210(suppl 1):S1-11.
4. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
5. Hend erson DA, Witte JJ, Morris L, Langmuir AD. Paralytic disease associated with oral polio vaccines. J Am Med Assoc 1964; 190:41-8.
6. Kew OM, Sutter RW, Nottay B, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998; 36:2893-9.
7. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. Evo lution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 1999; 265:178-84.
8. Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9.
9. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 2003; 9:885-7.
10. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, April 2011-June 2012. Morbid Mortal Wkly Rep 2012; 61:741-6.
11. Li L, Ivanova O, Triki H, et al. Poliovirus excretion among persons with primary immune deficiency disorders: Summary of a seven-country study series. J Infect Dis 2014; 210(suppl 1):S368-72.
12. Fine PEM, Carneiro IAM. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999; 150:1001-21.
13. Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2013-2018). http://www.polioeradication.org/portals/0/document/resources/strategywork/endgamestratplan-20130414-eng.pdf. Accessed 14 March 2014.
14. Jegouic S, Joffret M-L, Blanchard C, et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Path 2009; 5: e1000412.
15. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J AmMed Assoc 2004; 292:1696-701.
16. Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers in persons with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull WHO 2004; 82:3-8.
17. Alexander JP Jr., Gary HE Jr., Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997; 175(supp l 1):S176-82.
18. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 2008; 82:4429-40.
19. Burns C, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013; 87:4907-22.
20. Minor PD, Dunn G. The effect of sequences in the 5? non-coding region on the replication of polioviruses in the human gut. J Gen Virol 1988; 69:1091-6.
21. Macadam AJ, Arnold C, Howlett J, et al. Reve rsion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 1989; 172:408-14.
22. Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993; 192:18-26.
23. Yang C-F, Naguib T, Yang S-J, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983 to 1993. J Virol 2003; 77: 8366-77.
24. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004; 363:1509-13.
25. DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011; 364:2316-23.
26. Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199:391-7.
27. World Health Organization. Tracking progress towards global polio eradication, 2011-2012. Wkly Epidemiol Rec 2013; 88:153-60.
28. World Health Organization. Polio laboratory manual. 4th ed. Geneva: World Health Organization, 2004.
29. Kilpatrick DR, Yang C-F, Ching K, et al. Rapid group-, serotype-, and v accine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol 2009; 47:1939-41.
30. Kil patrick DR, Ching K, Iber J, et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J Virol Methods 2014; 197:25-8.
31. Centers for Disease Control and Prevent ion. Update on vaccine-derived polioviruses. Morbid Mortal Wkly Rep 2006; 55:1093-7.
32. Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccinederived poliovirus in the Philippines in 2001. J Virol 2004; 78:13512-21.
33. Yan D, Li L, Zhu S, et al. Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, Ch ina. J Clin Microbiol 2010; 48:3274-80.
34. World Health Organization. Circulating vaccine-derived poliovirus cases, 2000-2014. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circ ulatingvaccinederivedpoliovirus.aspx. Accessed 14 March 2014.
35. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Pallansch MA, Kew OM. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant duri ng widespread circulation in China. J Virol 2000; 74:11153-61.
36. Liang X, Zhang Y, XuW, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis 2006; 194:545-51.
37. Estívariz CWatkins MA,Handoko D,et al. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia 2005. J Infect Dis 2008 197 347-54.
38. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. Morbid Mortal Wkly Rep 2007; 56:996-1001.
39. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, July 2009-March 2011. Morbid Mortal Wkly Rep 2011; 60:846-50.
40. Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis 2008; 197:1427-35.
41. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. New Engl J Med 2010; 362:2360-9.
42. Wassilak S, Pate MA, Wannemuehler K, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria, 2005- 2009: emergence and widespread circulation in an underimmunized population. J Infect Dis 2011; 203:898-909.
43. Gumede N, Lentsoane O, Burns CC, et al. Emergence of vaccinederived polioviruses, Democratic Republic of Congo, 2004-2011. Emerg Infect Dis 2013; 19:1583-9.
44. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. Morbid Mortal Wkly Rep 2009; 58:1002-6.
45. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, July 2012-December 2013. Morbid Mortal Wkly Rep 2014; 63:242-8.
46. Arita M, Zhu SL, Yoshida H, Yoneyama T, Miyamura T, Shimizu H. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J Virol 2005; 79:12650-57.
47. Brown B, Oberste MS, Maher K, Pallansch M. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the non-capsid coding region. J Virol 2003; 77:8973-84.
48. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Kew OM, Pallansch MA. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J Virol 2003; 77: 10994-1005.
49. Martí n J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 2000; 74:3001-10.
50. Yang C-F, Chen H-Y, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 2005; 79:12623-34.
51. MacCallum FO. Hypogammglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Med Res Counc Spec Rep Ser 1971; 310:72-85.
52. Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Develop Biologic 2001; 105:75-80.
53. Martín J . Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006; 34:117-22.
54. Labadie K, Pelletier I, Saulnier A, Martin J, Colbere-Garapin F. Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology 2004; 318:66-78.
55. Yoneyama T, Hagiwara A, Ha ra M, Shimojo H. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect Immun 1982; 37:46-53.
56. Hara M, Saito Y, Komatsu T, et al. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol 1981; 2 5:905-13.
57. Khetsuriani N, Prevots DR, Quick L, et al. Persistence of vaccinederived polioviruses among immunodeficient persons with vaccineassociated paralytic poliomyelitis. J Infect Dis 2003; 188:1845-52.
58. Misbah SA,Lawrence PA,Kurtz JB,Chapel HM. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgrad Med J 1991 67 301-3.
59. Shahmahmoodi S, Mamishi S, Aghamohammadi A, et al. Vaccineassociated paralytic poliomyelitis in immunodeficient children, Iran, 1995- 2008. Emerg Infect Dis 2010; 16:1133-6.
60. Hidalgo S, Garcí a ErroM, Cisterna D, Freire MC. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J 2003; 22:570-2.
61. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Morbid Mortal Wkly Rep 2004; 53:990-3.
62. Tha rmaphornpilas P. Vaccine-derived poliovirus, Thailand, 2003. Emerg Infect Dis 2005; 11:777-8.
63. Parvaneh N, Shahmahmoudi S, Tabatabai H, et al. Vaccine-Associated paralytic poliomyelitis in a patient with MHC class II deficiency. J Clin Virol 2007; 39:145-8.
64. Shahmahmoodi S, Parvaneh N, Burns C, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child wit h X-linked agammaglobulinemia. Virus Res 2008; 137:168-72.
65. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses-worldwide, January 2007- June 2008. Morbid Mortal Wkly Rep 2008; 57:967-70.
66. de Silva R, Gunasena S, Ratnayake D, et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune defi ciency disorders in Sri Lanka. Vaccine 2012; 30:7561-5.
67. Gumede N, Muthambi V, Schoub BD. Immunodeficiency-Associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011. Emerg Infect Dis 2012; 18:992-4.
68. Cochi SL, Linkins RW. The final phase of polio eradication: new vaccines and complex choices. J Infect Dis 2012; 205:169-71.
69. Nat hanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010; 172:1213-29.
70. Wringe A, Fine PEM, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 2008; 3:e3433.
71. Sutter RW, Prevots R. Vaccine-Associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994; 11:426-38.
72. Yong PFK, Thaventhiran JED, Grimbacher B. " A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol 2011; 111:47-107.
73. Hennessey KA, Lago H, Diomande F, et al. Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d' Ivoire. J Infect Dis 2005; 192:2124-8.
74. Khetsuriani N, Helfand R, Pallansch M, et al. Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency vi rus infected children in Kenya. BMC Infect Dis 2009; 9:136.
75. Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. In vitro antiviral activity of V-073 against pol ioviruses. Antimicrob Agents Chemother 2009; 53:4501-3.
76. Al-Hello H, Jorba J, Blomqvist S, Raud R, Kew O, Roivainen M. Highly divergent types 2 and 3 vaccine-derived polioviruses isolated f rom sewage in Tallinn, Estonia. J Virol 2013; 87:13076-80.
77. Korotkova EA, Park R, Cherkasova EA, et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a pos sible scenario for the future. J Virol 2003; 77:12460-65.
78. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003. Morbid Mortal Wkly Rep 2003; 52:913-6.
79. Shulman LM, Manor Y, Sofer D, et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One 2006; 1:e69.
80. Cernákov á B, Sobotová Z, Rovny I, Blá hova S, Roivainen M, Hovi T. Isolation of vaccine-derived polioviruses in the Slovak Republic. Euro J Clin Microbiol Infect Dis 2005; 24:438-9.
81. Hovi T, Paananen A, Blomqvist S, et al. Characteristics of an environmentally monitored prolonged type 2 vaccine derived poliovirus shedding episode that stopped without intervention. PLoS One 2013; 8: e66849.
82. Blomqvist S, Savolainen C, Laine P, et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol 2004; 78:4876-83.
83. Roivainen M, Blomqvist S, Al-Hello H, et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surv 2010; 15:pii/19566.
84. Adu FD, Iber J, Bukbuk D, et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res 2007; 127:17-25.
85. Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33:680-702.
86. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013-conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:1-20.